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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is characterised by irreversible airflow obstruction, neutrophilic
airway inflammation and chronic bacterial colonisation, however the role of the innate immune response in the
pathogenesis of COPD remains unclear.
Methods: Induced sputum was obtained from adults with COPD (n=22), and healthy controls (n=29) and was processed
for differential cell counts. The sputum supernatant was assayed for innate immune mediators using ELISA, whilst sputum
gene expression was measured using real-time PCR. Peripheral blood neutrophils were isolated and their response to
lipopolysaccaride (LPS) stimulation was assessed in a subgroup of participants with COPD (n=13) and healthy controls
(n=21).
Results: Participants with COPD had significantly higher protein levels of interleukin (IL)-8, and neutrophil elastase (NE) and
detection of oncostatin M (OSM) compared to healthy controls. Gene expression for toll-like receptor (TLR) 2, IL-8 and OSM
were also significantly higher in COPD participants. The level of IL-1b, surfactant protein (SP)-A, matrix metalloproteinase
(MMP)-9 and TLR4 mRNA was not significantly different between groups. The level of innate immune response markers
were highly associated with the presence of sputum neutrophils, each other and the degree of airflow limitation (FEV1/FVC).
Peripheral blood neutrophils from participants with COPD had an increased response to stimulation by LPS; with a greater
fold increase in the production of IL-8 and MMP-9 protein, and gene expression of IL-8, TLR2 and TLR4.
Conclusions: The innate immune response is increased in the airways and circulating neutrophils in COPD, and may be an
important mechanism involved in disease pathogenesis.
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Introduction
Chronic obstructive pulmonary disease (COPD) is responsible
for a major and increasing burden of illness and death around the
world. It is currently the fourth leading cause of death in most
industrialised countries, and by the year 2020 it is predicted to be
the third leading cause of death worldwide [1]. COPD is chronic
and progressive, is characterised by incompletely reversible airflow
obstruction, symptoms of dyspnoea, cough and sputum produc-
tion, and an abnormal inflammatory response involving neutro-
phils, macrophages and CD8
+ T lymphocytes in response to
noxious particles such as cigarette smoke [2,3].
The innate immune response in the airways involves the
detection of pathogen- or damage-associated molecular patterns
(PAMPs or DAMPs), by pattern recognition receptors (PRRs) such
as toll-like receptors (TLRs) on the cell surface and secreted
receptors such as the collectins such as surfactant proteins [4].
Activation of PRRs triggers a signalling cascade leading to the
activation of nuclear factor kappa-light-chain-enhancer of activat-
ed B cells (NF-kB), resulting in the production of inflammatory
chemokines and cytokines [5,6]. Triggers of the innate immune
response, including infection by bacteria or viruses, and environ-
mental exposures such as cigarette smoke and air pollution, are
common exposures in people with COPD. Persistent innate
immune activation has been linked to chronic inflammatory
airway diseases such as neutrophilic asthma, bronchiectasis [7] and
models of chronic airway disease [8]. This activation is thought to
be caused by the interaction of PRRs with viruses, bacteria,
reactive oxygen species and dead and damaged cells and leads to
the development and exacerbations of COPD [9,10].
The presence of neutrophils in the airways is increased in COPD
[3,11] and associated with increased levels of neutrophilic
inflammatory mediators including interleukin (IL)-8 [12]. Markers
of airway neutrophilic inflammation are correlated with COPD
disease progression [13], clinical severity [14] and exacerbations
[15]. Peripheral blood neutrophils show altered activity in both
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expression of cell surface adhesion molecules [16–18], upregulation
of genes relating to inflammation [19] and enhanced respiratory
burst [17].
While airway inflammation in COPD has been well charac-
terised, the inflammatory mechanisms resulting in this chronic and
destructive neutrophilic inflammation are not well understood.
Since COPD has been proposed as an ‘archetypal disease of innate
immunity’ [9] this study investigated the innate immune response
in both the airways and peripheral blood neutrophils of
participants with COPD compared to their healthy counterparts.
We hypothesised that people with COPD would express higher
levels of innate immune mediators in the airway, and show
features of systemic involvement with an increased response of
circulating neutrophils to innate immune stimulation with the
TLR4/2 agonist, lipopolysaccharide (LPS). To examine these
effects, we have examined a broad range of innate markers, in
both the systemic and airway compartments, examined TLR
signalling in response to the TLR4 agonist LPS, and related these
changes to smoking status and airflow obstruction.
Methods
Ethics Statement
The Hunter Area Health Service and The University of
Newcastle Research Ethics Committee’s approved this study. All
participantsgave informedwritten consent priortotheirinclusionin
this study.
Subjects and Design
Participants with COPD(n=22) had a clinical diagnosis of
symptomatic COPD. Healthy controls without respiratory disease
(n=29) were over the age of 40 years, had an FEV1.80% of
predicted and were matched for smoking status. Exclusion criteria
included a current or recent (past month) respiratory tract
infection, exacerbation of respiratory disease, or a course of oral
steroids or antibiotics in the previous month. Participants were
recruited from the Respiratory Ambulatory Care Service at John
Hunter Hospital and by advertisement.
Clinical Assessments
Participants underwent clinical assessment, spirometry, combined
hypertonic saline challenge and sputum induction, allergy skin prick
testing, and in some cases blood collection. Information was col-
lected regarding smoking history, and the St George Respiratory
Questionaire was completed to assess quality of life. The carbon
monoxide transfer co-efficient (KCO) was determined according to
ATS guidelines (Med-Graphics DX Pulmonary function testing
system, Medical Graphics Corporation,Minnesota,MN, USA)[20].
Sputum Induction and Analysis
Spirometry (KoKo PD Instrumentation, Louisville, CO, USA)
and combined bronchial provocation testing and sputum induction
with hypertonic saline (4.5%) were performed as previously
described [21]. 100 mL of selected sputum was transferred to
RLT buffer (Qiagen, Hilden, Germany) and stored at 280uC. An
aliquot of sputum was used for bacteriological culture, and bacterial
identification was determined by the Hunter Area Pathology
Service. The remaining selected sputum was dispersed using
dithiothreitol as described [21]. The suspension was filtered, and
a total cell count (TCC) of leucocytes and viability performed.
Sputum supernatant was was stored at 280uC, until mediator
analysis and cytospins were prepared from the cell pellet, stained
and a differential cell count obtained from 400 non-squamous cells.
Detection of Mediators
The concentrations of IL-8, IL-1b, TNF-a, OSM and Total
MMP-9 protein were determined by ELISA (R&D Systems,
Minneapolis, MN, USA), and NE by the Innozyme Human
Neutrophil Elastase Immunocapture Activity Assay Kit (Calbio-
chem, La Jolla, CA, USA) as per manufacturer’s instructions.
Target gene expression was analysed using quantitative real-time
PCR as described previously [22]. Briefly, RNA was extracted and
reverse-transcribed to cDNA. Taqman qPCR probes for IL-8,
OSM, TLR2 and TLR4 mRNA were purchased in kit form,
combined with the reference gene eukaryotic 18S ribosomal RNA
in duplex real-time PCRs (ABI 7500 Real Time PCR Machine,
Applied Biosystems, Foster City, CA, USA) and results calculated
using 2
-DDCt relative to the housekeeping gene (18S) and an
internal calibrator.
Peripheral Blood Neutrophil Culture
Peripheral blood neutrophils were isolated using Percoll density
gradient and magnetic cell separation as previously described [23].
Cells were resuspended in RPMI1640 (Gibco Invitrogen, Mount
Waverley, Australia) with 10 mM HEPES, 1% fetal calf serum
and antibiotics (Penicillin/Streptomycin). Cells were cultured at
1610
6cells/ml +/2 LPS (10 or 100 ng/ml E.coli LPS, Sigma,
Sydney, Australia) at 37uC (5% CO2) for 24 hours before cell free
supernatants were prepared and cell pellets were and stored in
RLT buffer (Qiagen, Hilden, Germany) at 280uC until further
analysis.
Data Analysis
Data were analysed using Stata 9 (Stata Corporation, College
Station, Texas USA), with results reported as median and
interquartile range unless otherwise indicated. Analysis was
performed using the two-sample Wilcoxon Rank Sum test. Chi
squared or fischers’ exact tests was applied to analyse categorical
data. Associations between data were determined using Spear-
man’s rank correlation. Results were reported as significant when
p,0.05.
Results
Clinical parameters
Participants with COPD were older and had considerably lower
lung function, but were similar to healthy controls in terms of
gender and atopy (Table 1). About half of participants with COPD
(n=10, 45%) were taking inhaled corticosteroid therapy (2000
(2000, 2000) mg beclomethasone equivalents/day). COPD severity
was classified as mild (stage I, n=3 (14%)), moderate (stage II,
n=17 (77%)), and severe (stage III, n=2 (9%)) according to
GOLD criteria. Smoking history and pack years smoked were
significantly greater in the COPD group (Table 1).
Inflammatory Cells
Participants with COPD had a significantly increased total cell
count, proportion and number of neutrophils and eosinophils
(Table 2). The proportion of macrophages was lower in
participants with COPD; however numbers of macrophages did
not differ between groups.
Airway Innate Immune Mediators
OSM protein was not detectable in healthy participants,
however OSM was detected significantly more in COPD with
26% (n=5; p=0.046; 1349.9(867.8, 1820.1) pg/mL) of samples at
detectable levels. Gene expression of TLR2 (Figure 1A; p=0.021),
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significantly increased in COPD, whereas gene expression for TLR4
[Healthy: 5.8(4.3–7.5); COPD: 6.7(4.9–8.4); p=0.621] remained
unchanged. Participants with COPD had significantly higher levels
IL-8 (Figure 2A; p#0.001) and NE (Figure 2B; p=0.015) protein,
and higher levels of total MMP-9, however this did not reach
statistical significance (Figure 2C; p=0.168). The level of SP-A
[Healthy: 47.9 (34.8–96.8); COPD: 50.5 (44.6–98.7); p=0.285] or
IL-1b[Healthy:15.7(1.6–39.3);COPD:35.7(15.3–71.3);p=0.236]
protein did not differ between participants with COPD and healthy
controls. A sub analysis of participants taking inhaled corticosteroid
(ICS) compared to those not taking ICS showed that ICS use did not
alter airway mediator levels in COPD.
Associations
Strong correlations were observed between markers of the
innate immune response including sputum neutrophils, TLR2
gene expression, IL-8, MMP-9 and NE protein (Table 3). There
was a positive correlation between sputum neutrophil % and the
gene expression of TLR2 (r=0.59; Figure 3). There were
significant negative correlations between measures of airflow
obstruction and inflammatory markers. FEV1/FVC was signifi-
cantly negatively correlated with sputum neutrophil% (r=20.34;
p=0.033), sputum neutrophil number (r=20.33; p=0.037), level
of IL-8 (r=20.49; p=0.002) and NE (r=20.41; p=0.012). In
addition, FEV1% predicted was significantly negatively correlated
with the level of IL-8 (r=-0.42; p=0.009).
Table 1. Clinical characteristics of subjects with COPD and healthy control subjects.
Healthy Controls COPD p
N 29 22
Age years, mean (SD) 59 (10) 67 (7) 0.001
Gender M | F 12 | 17 15 | 7 0.058
Body Mass Index, mean (SD) 27.0 (6.1) 28.4 (5.7) 0.414
Atopy n (%) 17 (59) 11 (50) 0.540
Smoking, Never | Ex | Current 12 | 12 | 5 2 | 17 | 3 0.021
Pack years, median (Q1, Q3) 13 (4, 35) 63 (31, 75) 0.001
FEV1% predicted, post bronchodilator, mean (SD) 99 (11) 67 (11) ,0.001
FVC% predicted, post bronchodilator, mean (SD) 78 (12) 53 (9) ,0.001
FEV1/FVC %, mean (SD) 76 (5) 61 (8) ,0.001
FEF 25–75% predicted, post bronchodilator, mean (SD) 76 (24) 33 (9) ,0.001
KCO % Predicted, mean (SD) 79.5 (12.6) 63.3 (20.3) ,0.001
Quality of Life Score, total, median (Q1,Q3) 4 (1, 5) 35 (16, 46) ,0.001
Culture positive n (%) 0 (0) 3 (14) 0.037
doi:10.1371/journal.pone.0018426.t001
Table 2. Inflammatory cell counts for participants with COPD and healthy controls.
Healthy Controls COPD p
n 25 19
Total cell count 610
6/mL 2.1 (1.6, 4.3) 4.9 (2.8, 10.7) ,0.001
Viability 84.3 (72.7, 88.5) 88.7 (80.7, 91.3) 0.267
Neutrophils, % 36.0 (24.5, 47.8) 53.8 (35.8, 68.0) 0.011
Neutrophils 10
4/mL 92.9 (32.1, 173.5) 197.9 (147.9, 590.0) 0.005
Eosinophils, % 0.1 (0.0, 0.5) 0.8 (0.3, 2.3) 0.013
Eosinophils 10
4/mL 0.2 (0.0, 1.2) 4.5 (1.3, 12.6) ,0.001
Macrophages, % 57.8 (48.0, 66.8) 41.3 (27.8, 48.5) 0.003
Macrophages 10
4/mL 125.7 (85.4, 216.0) 171.7 (115.1, 288.0) 0.108
Lymphocytes, % 1.5 (0.4, 3.1) 1.0 (0.3, 2.0) 0.398
Lymphocytes 10
4/mL 3.7 (1.1, 6.2) 4.2 (1.2, 12.0) 0.405
Columnar epithelial cells, % 1.3 (0.6, 3.1) 1.3 (0.8, 2.8) 0.704
Columnar epithelial cells 10
4/mL 2.6 (1.4, 7.2) 6.0 (1.8, 16.7) 0.382
Squamous cells, % 3.0 (1.1, 6.7) 1.7 (0.2, 2.9) 0.086
Results shown are median (Q1, Q3).
doi:10.1371/journal.pone.0018426.t002
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The impact of smoking status was investigated by repeating the
analysis of innate immune response markers after removal of all
participants that were never smokers. This did not change the
outcomes measured. Ex and current smoking participants with
COPD had significantly more OSM detected (p=0.036),
significantly higher gene expression of TLR2 (p=0.019), IL-8
(p=0.030) and OSM (p=0.028), and significantly higher levels of
IL-8 (p,0.001), NE (p=0.013) and higher levels of MMP-9
(p=0.13) compared to healthy ex and current smokers. However,
there was positive correlation between the degree of smoking
history (pack years smoked) with the number of airway neutrophils
(r=0.39; p=0.024); the level of IL-8 ng/ml (r=0.51; p=0.003)
and NE ng/mL (r=0.49; p=0.005); and negative correlation with
FEV1% predicted (r=20.37; p=0.026) and FEV1/FVC
(r=20.45; p=0.005).
Peripheral Blood Neutrophil Responses
Peripheral blood neutrophils isolated from participants with
COPD had exaggerated innate immune responses to stimulation
with LPS. There were higher fold increases observed for IL-8 and
MMP-9 protein, and IL-8, TLR2 and TLR4 mRNA (Figure 4;
Clinical details of participants are shown in Table 4).
Discussion
This study investigated the innate immune response of
neutrophils in both the airway and systemic compartments in
participants with COPD and examined responses in relation to the
degree of airflow obstruction. In airway samples from COPD
participants, there was increased constitutive expression of innate
immune response markers, and in the systemic compartment there
was an increased innate immune response of circulating
neutrophils to a TLR4 agonist. Gene expression for TLR2 was
increased in airway samples in COPD, and there was enhanced
TLR2 and TLR4 gene expression in circulating neutrophils with
LPS stimulation, demonstrating the potential for chronic activa-
tion of innate immune responses. The consequences of this was
increased levels of IL-8, NE, MMP-9 and OSM protein detected
in the airways of participants with COPD as well as an
upregulation of IL-8, OSM, TLR2 gene expression. The innate
immune mediators IL-8, NE, MMP-9 and TLR2 were highly
correlated with airway neutrophils and each other, suggesting a
positive feedback cycle of neutrophilic airway inflammation [24].
This cycle is likely to impact on lung function and particularly the
degree of airflow limitation, as significant correlations were
observed between FEV1/FVC with sputum neutrophils, IL8 and
NE protein. Furthermore, in COPD, systemic neutrophils showed
a significantly increased response to in vitro LPS stimulation in the
way of IL-8, and MMP-9 production.
These results indicate that the innate immune response is active
both systemically and in the airways in stable COPD. The
presence of increased numbers of neutrophils in the airways of
COPD patients together with increased levels of neutrophilic
inflammatory mediators in airway samples, including cytokines
such as IL-8 and TNF-a, and proteases such as NE and MMP-9
[12,25,26] has been observed previously. Our study confirms the
increased production of IL-8 and NE, and makes the novel
observation that OSM, an IL-6 family cytokine, was detected
more frequently in the airways of COPD patients. OSM plays an
Figure 1. Gene expression of IL-8 (A), TLR2 (B) and OSM (C) was increased in the airways of participants with COPD (dark grey)
compared to healthy controls (light grey). Data reported as median with the error bar as the 3
rd quartile. *p,0.05 versus healthy controls.
doi:10.1371/journal.pone.0018426.g001
Figure 2. IL-8 (A), HNE (B) and MMP-9 (C) protein levels were higher in the airways of participants with COPD (dark grey) compared
to healthy controls (light grey). Data reported as median with the error bar as the 3
rd quartile. *p,0.05 versus healthy controls.
doi:10.1371/journal.pone.0018426.g002
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shown to be increased in asthma and airway obstruction [28].
Interestingly, IL-1b was not elevated, and has recently been shown
to be suppressed by cigarette smoke exposure [29].
TLRs present on neutrophils are thought to mainly be involved
in antibacterial responses, including the recognition of gram
positive bacteria by TLR2 [30], and gram negative bacteria by
TLR4 [4] and bacterial DNA by TLR-9 [31]. Activation of
TLR2, TLR4 and TLR9 regulates several important neutrophil
functions through the activation of the NF-kB pathway, including
neutrophil activation, migration and survival [32]. We have
previously reported an upregulation of TLR2 associated with
neutrophilic airway inflammation in neutrophilic asthma [7]. We
now show that TLR2 mRNA is upregulated in COPD, and that
TLR2 and TLR4 expression increase dramatically upon LPS
stimulation of blood neutrophils. This indicates that these cells
upon stimulation would have an increased capacity to respond to
innate immune triggers important in COPD pathogenesis.
Cigarette smoking is widely recognised as a primary risk factor
for the development of COPD, and participants with COPD in
our study had a greater history of smoking than our control group.
Components of cigarette smoke can cause an inflammatory
response upon inhalation and this exposure is considered to be
the starting point disease pathogenesis in COPD [33]. We found
that smoking dose was positively correlated with inflammatory
mediator levels. It is not fully understood how the innate immune
system responds to cigarette smoke, however it has been proposed
that the injury to the airway epithelium produces ‘danger signals’
or DAMPs that can act as ligands for TLRs including TLR2,
TLR4 [34] and TLR9 [31]. This results in the activation of NF-kb
and the production of inflammatory mediators that attract
neutrophils and macrophages [35]. The inflammatory response
caused by exposure of mice to cigarette smoke has been reported
to be dependent on both TLR4 and IL1R1 signalling involving the
associated protein myeloid differentiation factor 88 (MyD88) [36].
The inflammatory response in COPD is not limited to the lungs,
but may also be seen in the systemic compartment [37]. We have
demonstrated that blood neutrophils in COPD have an increased
response to in vitro LPS stimulation, with increased production of
IL-8, OSM, and release of MMP-9. This enhanced response could
contributesignificantlytothesystemicinflammationseeninCOPD,
as well as the migration of cells to the pulmonary compartment.
Other studies have shown an enhanced activation of systemic
neutrophils in COPD, particularly a potentiation of migratory and
cytotoxic responses [16–18], but also upregulation of inflammatory
genes [19]. We have previously shown that alterations in cytokine
production and gene expression of circulating neutrophils are
important in non-eosinophilic asthma [38], which is also associated
with neutrophilic airway inflammation.
Interestingly, airway levels of IL-8, NE, MMP-9, TLR2 mRNA
and neutrophils were highly correlated, indicating that these
mediators are both associated with neutrophilic airway inflamma-
tion and each other. We have previously proposed that the
production of IL-8, NE and MMP-9 occurs in a positive feedback
cycle that leads to persistence of neutrophilic inflammation in the
airways, and that this is postulated to be due to amplification of the
innate immune response involving stimulation of TLR2 [24]. The
data reported here further corroborate these findings, and show
similarities between neutrophilic inflammation seen in COPD as
to that previously reported in neutrophilic asthma, suggesting a
common mechanism [7,39]. The data also suggest a common
pathogenic network may be operating to mediate the tissue
responses seen in COPD [40]. Insight into the role of the innate
immune response is of high relevance for the identification of
further diagnostic and therapeutic approaches. Development of
treatments targeted at reducing neutrophilic airway inflammation
would be of great benefit for the treatment of COPD [9].
Neutrophils are key effector cells in COPD, and our
observations that the presence of airway neutrophils and the level
of IL-8 and NE relate to the severity of airflow obstruction extend
these observations. We have also shown that the number of pack
Table 3. Correlation matrix for innate immune response markers.
Neutrophil, % TLR2 mRNA Total MMP-9 IL-8 ng/mL NE ng/mL
Neutrophils 10
4/mL 0.82
c 0.38 0.56
b 0.74
c 0.71
c
Neutrophil, % 0.59
b 0.65
c 0.61
c 0.66
c
TLR2 mRNA 0.38 0.32 0.43
a
Total MMP-9 0.55
b 0.62
b
IL-8 ng/mL 0.79
c
Spearman
ap,0.05,
bp,0.001,
cp,0.0001.
doi:10.1371/journal.pone.0018426.t003
Figure 3. Sputum neutrophil % and TLR2 gene expression are
significantly correlated (Spearman R=0.59; p=0.001).
doi:10.1371/journal.pone.0018426.g003
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obstruction and positively correlated with the accumulation of
airway neutrophils. This suggests that cigarette smoking can
influence the accumulation of airway neutrophils, which is
associated with production of innate immune mediators and an
increase in airflow obstruction.
In summary, we have shown that participants with COPD had
significantly higher levels of airway IL-8, NE, OSM, and TLR2
mRNA and an increased release of IL-8, MMP-9 and OSM
protein, and gene expression of IL-8, OSM, TLR4 and TLR2
from peripheral blood neutrophils in response to in vitro TLR
stimulation. IL-1b and SP-A were not implicated in this response.
This increased innate immune response both in the airways and
peripheral blood neutrophils in COPD further implicates the
Figure 4. Peripheral blood neutrophils isolated from participants with COPD (dark grey) had a greater increase in the production of
IL-8 (A) and MMP-9 (B) protein and the gene expression of IL-8 (C), TLR2 (D), and TLR4 (E) in response to LPS stimulation compared
to healthy controls (light grey). Data expressed as fold increase versus media control.*p,0.05 versus healthy controls.
doi:10.1371/journal.pone.0018426.g004
Table 4. Clinical details of participants with COPD and
healthy controls in whom in vitro LPS responses of peripheral
blood neutrophils were assessed.
Healthy COPD p
N 21 13
Age years, mean (SD) 56 (20) 67 (6) 0.065
Gender M | F 10 | 11 6 | 7 0.934
FEV1% predicted, mean (SD) 103 (13) 61 (16) ,0.001
FEV1/FVC %, mean (SD) 86 (11) 68 (16) ,0.001
doi:10.1371/journal.pone.0018426.t004
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mechanism of disease pathogenesis. Both bacterial colonisation
and cigarette smoking are likely triggers of this aberrant
neutrophilic response.
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